Cagrilintide
Long-acting amylin analog investigated for weight management alongside GLP-1 pathways.
Overview
Discussed in combination trials with incretin-based therapies — always label- and prescriber-driven.
What it is
Synthetic amylin receptor agonist peptide.
Mechanism (high level)
Targets amylin satiety pathways; nausea and GI effects are common class considerations.
Quick facts
- Dosage
- Per approved label / trial protocol only
- Route
- Subcutaneous (when prescribed)
- Cycle
- Titrate per specialist
- Storage
- Per manufacturer cold-chain requirements
Research indications
- Obesity and metabolic trial literature
Research protocols (education)
Education-first logging template
Use PepTok to track adherence and notes; any protocol must be directed by a qualified clinician.
Interactions
Often avoided with
- Other GLP-1/GIP agents without specialist coordination
Often combined with
- Structured nutrition counseling
Peptides discussed online are not substitutes for diagnosis or prescriptions.
Side effects & safety
- Nausea, vomiting, GI upset — seek care for persistent symptoms.
Regulatory notes
- Prescription status varies; follow local approvals.
FAQ
Is this a prescription?
PepTok does not provide prescriptions; it is for logging and education.
Related in catalog
Track in app
Save favorites, compare protocols, and track over time
PepTok gives you structure: stacks, reminders, notes, and progress snapshots in one place.
Educational content only. This material is not medical advice. Verify legality, sourcing, and dosing with a qualified professional.